Patriot Financial Group Insurance Agency LLC Has $6.01 Million Position in Becton, Dickinson and Company $BDX

Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 119.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,198 shares of the medical instruments supplier’s stock after buying an additional 20,799 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Becton, Dickinson and Company were worth $6,006,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Crux Wealth Advisors raised its position in Becton, Dickinson and Company by 0.8% in the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 49 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares during the last quarter. Camelot Portfolios LLC increased its stake in shares of Becton, Dickinson and Company by 1.5% in the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC raised its holdings in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after buying an additional 55 shares during the last quarter. Finally, Atlantic Union Bankshares Corp boosted its position in Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after buying an additional 57 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDX. Argus decreased their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. TD Cowen decreased their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, Bank of America reduced their price target on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $181.00.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $156.06 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a fifty day moving average of $148.17 and a 200-day moving average of $170.75. The firm has a market capitalization of $43.00 billion, a P/E ratio of 39.51, a P/E/G ratio of 11.04 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period last year, the company posted $3.35 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.